Functional state of the lower urinary tract in men with bladder outlet obstruction

F Introduction: In most patients with obstructive symptoms, micturition disorders are caused by both mechanical and functional factors. The study of urination disorders and correct interpretation of the findings can reveal the severity of the disease, clarify its prognosis, and influence in the determination of the timing and method of therapy. Aim: to determine the functional state of the lower urinary tract in men with bladder outlet obstruction. Materials and methods: We have analyzed the medical history of 270 patients with various obstructive diseases of the lower urinary tract who were treated at the Urological Clinic of Sechenov University. A combined urodynamic study was performed in 206 patients to find out the functional state of the lower urinary tract. Results: In 120 (58.25%) patients detrusor overactivity was revealed, low compliance of detrusor - in 45 (21.85%) patients, high compliance of detrusor - in 30 (14, 56%), normal compliance - in 11 (5.34%). The average length of complaints in patients with detrusor overactivity was 5.34 years, with low compliance of detrusor - 6.16 years, with high compliance of detrusor - 4.34 years. The maximum cystometric volume of the bladder in patients with OAB was 183.59 ml, and the average wave of detrusor pressure was 73.44 cm H2O. Functional component of the bladder outlet obstruction after surgery operation was detected in 12.5% of patients. Conclusions: According to our results, the most frequently in urodynamic study of patients revealed detrusor overactivity (58.25% of patients). This bladder dysfunction was the main leading link in the development of complications of the bladder outlet obstruction, vesicoureteral reflux, ureterohydronephrosis and as a result of pronounced disturbances in the urodynamics of the upper urinary tract - chronic renal failure.

функциональное состояние мочевого пузыря, инфравезикальная обструкция, уродинамические исследования, functional state of the bladder, bladder outlet obstruction, urodynamic studies

1. Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 2006; 49:651

2. Sexton CC, Coyne KS, Kopp ZS et al. The overlap of storage, voiding and postmicturition symptoms and impli- cations for treatment seeking in the USA, UK and Sweden: EpiLUTS. BJU Int 2009; 103 (Suppl 3): 12-23

3. Jensen K.M-E., Jorgensen JB., Mogensen P. Urodynamics in prostatism I-IV. Prognostic value of uroflowmetry. Scand J Urol Nephrol 1988a; 22:109-17.

4. Hald T., Kroyer K. Nielsen, Nordling J. Клиническая уродинамика при доброкачественной гиперплазии простаты// European Urology Update Series, 1993 (Hald T. Urodunamics in benign hyperplasia: a survey. Prostate (Suppl), 1989; 2: 69-77).

5. Andersen JT, Nordling J. The correlation between cistourethroscopic, cystometric and urodinamic findings// Scand J UrolNephrol. 1980

6. Jensen K.M-E., Andersen JT. Urodynamics implication of benign prostatic hyperplasia. Urologe [A] 1990;29: 1-4;.

7. Nielsen, K.K. Morphological, stereological, and biochemical analysis of the mini-pig urinary bladder after chronic outflow obstruction and after recovery from obstruction / K.K. Nielsen, C.B. Andersen, L.K. Petersen, H. Oxlund, J. Nordling // Neurourology and urodynamics. - 1995. - No14 (3). - P. 269-284

8. Портной А.С. Патогенетические механизмы аденомы и рака предстательной железы. Л.: Медицина, 1970.

9. Портной А.С. Хирургическое лечение аденомы предстательной железы. М., 1965.

10. Пытель Ю.А., Воркунов И.Я. Исследование функции почек у больных аденомой предстательной железы радиоизотопной ренографией. Урология и нефрология. 1965;6:11-18

11. Лопаткин Н.А. «Руководство по урологии» в 3-х томах. - М.:Медицина. -1998

12. Осипов И.Б. Реконструктивно-пластические операции при экстрофии мочевого пузыря у детей: Методические рекомендации. СПб.: СПбГПМА, 1995. 28 с.,

13. Лопаткин Н.А., Пугачев А.Г. Детская хирургия. Руководство. М.: Медицина, 1986. 496 с,

14. Джавад-Заде М.Д. и Державин В.М. Нейрогенные дисфункции мочевого пузыря. // М. «Медицина», 1989. С. 101-137, 384

15. O’Leary Michael P. «Симптомы нижних мочевых путей /Доброкачественная гиперплазия простаты: поддержание контроля над симптомами и предупреждение осложнений. Приложение к журналу “Урология " (UROLOGY), 2003, том 62, №3А

16. Abrams P. H., Griffiths D. J. The assessment of prostatic obstruction from urodynamic measurements and from residual urine // Br. J. Urol. - 1979. - Vol.51. - P.129-134

17. Abrams PH, Farrar DJ, Turner-Warwick RT, Whiteside CG, Feneley RC: The results of prostatectomy: A symptomatic and urodynamic analysis of 152 patients. J Urol 1979; 121:640-642

18. Ameda K, Koyanagi T., Taniguchi K., Matsuno T. The relevance of preoperative cystometrography in patients with benign prostatic hyperplasia: correlating the findings with clinical features and outcome after prostatectomy. J Urol 152: 443-447 (level V), 1994.

19. Knutson T., Edlung C., Fall M., Dahlstrand C. BPH with coexisting overactive bladder dysfunction - an everyday urological dilemma. Neurourol Urodyn 2001; 20: 237-247

20. Hashim H., Abrams P. Bladder outlet obstruction, bladder contractility and detrusor overactivity: is there a link. 6th International consultation on new developments in prostate cancer and prostate diseases. June 24-27, 2005, Paris, France. Abst.29

21. Fujimura T et al. J Urol 1999; 161: 680-5; Yamaguchi O. Urology 2002; 59(5 Suppl 1): 25-9

22. Yamaguchi O. Urology 2002; 59(5 Suppl 1): 25-9

23. Ouslander JG. N Engl J Med 2004; 350: 786-99

24. Montorsi F. Profile of silodosin. Eur Urol 2010; 4 Suppl. 9:491-5

25. Abdel-Khalek M., Nabieh A., Ibrahiem E. Do muscarinic receptors of the prostate have a significant role in the pathophysiology of bladder outlet obstruction? Phase 1 (in vitro) study. European Urology Supplements, Volume 5, issue 2 (April, 2006), p. 120

26. Restorick J., Mundy A. The Density of Cholinergic and Alpha and Beta Adrenergic Receptors in the Normal and Hyper-reflexic Human Detrusor. British Journal of Urology 1989; 63(1):32-5

27. Rohner T. Changes in Adrenergic Receptors in Bladder Outlet Obstruction (Benign prostatic hypertrophy. Edited by Frank Hinman, Jr. by Springer-Verlag New York Inc)- 1983 -p.410-413.

28. Пытель Ю.А., Винаров А.З. «Этиология и патогенез гиперплазии предстательной железы» В книге «Доброкачественная гиперплазия предстательной железы»М., 1999, стр.21-37

29. Вишневский А.Е. - Новые аспекты патогенеза расстройств мочеиспускания при доброкачественной гиперплазии простаты. Журнал «Лечащий врач» 2000, #11

30. Лоран, О.Б., Роль гипоксии детрузора в патогенезе расстройств мочеиспускания у больных доброкачественной гиперплазией предстательной железы / О.Б. Лоран, Е.Л. Вишневский, А.Е.Вишневский // Урология и нефрология. 1996.-№ 6. - С. 33 - 36

31. Лоран О.Б., Вишневский Е.Л., Вишневский А.Е. «Лечение расстройств мочеиспускания у больных доброкачественной гиперплазией простаты альфаадреноблокаторами» М., 1998 - 124 с.

32. Мазо Е.Б., Кривобородов Г.Г. Гиперактивный мочевой пузырь. М.: Вече, 2003

33. Holm N.R., Horn T., Hald T. Detrusor in ageing and obstruction. Scand J Urol Nephrol. 1995 Mar;29(1):45-9.

34. Sibley G.N. Physiological response of the detrusor muscle to experimental bladder outflow obstruction in the pig. Br J Urol. 1987 Oct; 60: 332-336.

35. Watson N. Reddy H. Eglen R. M. Pharmacological characterization of the muscarinic receptors mediating contraction of canine saphenous vein /7 J. Auton. Pharmacol. - 1995. - Vol. 15. - P. 37-441

36. Blaivas J., Marks B., Weiss J., Panagoupolos G., Somaroo C. Differential diagnosis of overactive bladder in men. J Urol. - 182: 2814-7;

37. Гаджиева З.К. / Под ред. Ю.Г. Аляева. Нарушения мочеиспускания (Серия - Библиотека врача-специалиста ) - Гэотар-Медиа. - 2010 - 176 с

38. Abrams, P.: Detrusor instability and bladder outlet obstruction. Neurourol Urodyn, 4: 317, 1985

39. Michel MC, Vrydag W. a1-, a2- and ß-Adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol 2006; 147: 88-119

40. Мельников А.В. Профилактика послеоперационной острой задержки мочеиспускания у мужчин альфа-1-адреноблокаторами. // Фундаментальные науки и прогресс клинической медицины. Материалы II Российской конференции молодых ученых России с международным участием. -(Москва, 24-28 апреля 2001) -М., 2001, Том II, с.218-219

41. Oelke M, Bachmann A, Descazeaud A et al. EAU guidelines on the management of male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO) 2012

42. Мазо Е.Б. Кривобородов Г.Г. Козырев С.В. Применение а-блокаторов и холинолитиков у больных доброкачественной гиперплазией простаты и гиперактивным мочевым пузырем. - «РМЖ» №12. - 2007 - стр. 1016

43. Saito, T. Yamada, H. Oshima, et al. A comparative study of the efficacy and safety of tamsulosin hydrochloride alone and combination of propiverine hydrochloride and tamsulosin hydrochloride in the benign prostatic hypertrophy with pollakisuria and/or urinary incontinence. Jpn J Urol Surg. 1999;12:525-536;

44. Athanasopoulos A.,, K. Gyftopoulos, K. Giannitsas, J. Fisfis, P. Perimenis, G. Barbalias. Combination treatment with an а-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol. 2003;169:2253-2256;

45. Lee KS, Kim DY2, Kim JC, et al. Combination treatment with propiverine hydrochloride plus doxazosin gits in men with overactive bladder coexisting benign prostatic obstruction: a prospective, randomized, controlled, multicenter study. 2004 ICS annual meeting [abstract 207];

46. Lee K.S., M.S. Choo, D.Y. Kim, et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. J Urol. 2005;174:1334-1338;

47. Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA. 2006 Nov 15;296(19):2319-28;

48. Kaplan SA, McCammon K, Fincher R, Fakhoury A, He W. Safety and tolerability of solifenacin add-on therapy to а-blocker treated men with residual urgency and frequency. J Urol 2009; 182: 2825-30

49. MacDiarmid SA, Peters KM, Chen A et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clin Proc 2008; 83:1002-10.58.

50. Chapple C, Herschorn S, Abrams P et al. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with -blockers. Eur Urol 2009; 56: 534-41.

51. Yamaguchi O, Kakizaki H, Homma Y et al. Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms-ASSIST, randomized controlled study. Urology 2011; 78: 126

52. Kaplan SA, Roehrborn CG, Gong J, Sun F, Guan Z. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving а-blocker treatment for lower urinary tract symptoms. BJU Int 2012; 109: 1831-40.

53. Yamaguchi O, Kakizaki H, Homma Y et al. Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms-ASSIST, randomized controlled study. Urology 2011; 78(1): 126-33.

54. Lee SH, Chung BH, Kim SJ et al. Initial combined treatment with anticholinergics and -blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multicenter, double-blind, placebo-controlled study. Prostate Cancer Prostatic Dis 2011; 14: 320-5.

55. Van Kerrebroeck P, Haab F, Angulo JC, et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN) Eur Urol. 2013;64(3):398-407.

56. Van Kerrebroeck P, Chapple C, Drogendijk T, et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. Eur Urol. 2013;64(6):1003-1012.

57. Drake M, Chapple C, van Kerrebroeck P, et al. Efficacy of combination therapy with tamsulosin OCAS and solifenacin in NEPTUNE: Results from a randomised, phase 3 trial in men with LUTS. Eur Urol. 2012 EAU Abstracts #746.H.

58. Гаджиева З.К. Уродинамические исследования в диагностике и лечении нарушений мочеиспускания. Дис....док. мед. наук. 2009 -М. -319 с.